IN THE SPECIFICATION

Please amend paragraph 5 as follows:

In one embodiment, a method of treating a human in need of cancer treatment comprises administering a composition comprising greater than 0.5 weight percent of a phytoestrogen based on the total weight of the composition, wherein the phytoestrogen is:

wogonin, its pharmaceutically acceptable esters and salts, and its selectively substituted analogs represented by formula (1)



(1)

wherein R^1 is hydrogen, C_1-C_6 alkyl, or C_1-C_6 alkoxy; R^2 is hydrogen, C_1-C_6 alkyl, or C_2-C_6 acyl; R^3 and R^4 are independently hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl; one of R^5 or R^6 is hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl, wherein the other of R^{5A} or R^{5B} is



wherein R^7-R^{11} are independently hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl; and wherein at least four of R^3-R^{11} are hydrogen;

isoliquiritigenin, its pharmaceutically acceptable esters and salts, and its selectively substituted analogs represented by the formula (2)



(2)

wherein R^{11}-R^{14} are independently hydrogen or C_1-C_6 alkyl; R^{15}-R^{20} are independently hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl, wherein at least three of R^{15}-R^{20} are hydrogen;

coumestrol, its pharmaceutically acceptable esters and salts, and its selectively substituted analogs represented by the formula (3)



(3)

wherein R^{21} and R^{22} are independently hydrogen or C_1-C_6 alkyl; and R^{23}-R^{28} are independently hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl, wherein at least three of R^{23}-R^{28} are hydrogen;

a prenyl isoflavonoid represented by formula (4)



(4)

wherein R^{30} and R^{31} are independently hydrogen or 3-methyl-2-butenyl, with the proviso that at least one of R^{31} and R^{31}~~R^{33}~~ is 3-methyl-2-butenyl; R^{29} and R^{32} are independently hydrogen or C_1-C_6 alkyl; and R^{33}-R^{37} are independently hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl; and wherein at least two of R^{33}-R^{37} are hydrogen;

or a combination comprising one or more of the foregoing phytoestrogens.

Please amend paragraph 55 as follows:

The phytoestrogen can comprise a prenyl flavonoid such as, for example, 6-prenylnarignin, 8-prenylnaringenin, and 6,8-diprenylnaringenin. Suitable prenyl isoflavonoids are represented by Formula



(4)

wherein R^{30} and R^{31} are independently hydrogen or 3-methyl-2-butenyl, with the proviso that at least one of R^{31} and $R^{31}R^{33}$ is 3-methyl-2-butenyl; R^{29} and R^{32} are independently hydrogen or C_1-C_6 alkyl; and R^{33}-R^{37} are independently hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl; and wherein at least two of R^{33}-R^{37} are hydrogen.